Digital Diagnostic Platform Uses Electronic Technology for Rapid Disease Detection

Now, a groundbreaking digital diagnostics platform aims to revolutionize point-of-care testing with real-time, high-sensitivity results.

The platform, developed by IdentifySensors Biologics (Shaker Heights, OH, USA), utilizes advanced graphene-based sensors integrated into a compact, reusable Bluetooth-enabled device. This technology allows for the detection of multiple pathogens from a single saliva sample without the need for enzymatic amplification or reagents, streamlining the diagnostic process. The system comprises a handheld reader and disposable test cartridges capable of identifying up to three pathogens simultaneously. By targeting conserved genomic regions, the platform ensures high specificity and sensitivity, surpassing traditional PCR tests in detecting viral concentrations as low as 200 copies per milliliter.

Preliminary clinical trials have demonstrated approximately 98% accuracy in rapid result delivery from verified COVID-19 samples. Beyond COVID-19, the platform is being developed to detect a broad spectrum of pathogens, including RSV, influenza, norovirus, rotavirus, adenovirus, HIV, hepatitis, chlamydia, gonorrhea, herpes, MRSA, Lyme disease, and tropical diseases like Zika and dengue. Its versatility and rapid turnaround make it a promising tool for both clinical settings and at-home testing, facilitating timely medical interventions and reducing disease spread. IdentifySensors has initiated the FDA review process by submitting a pre-EUA for emergency use authorization of a rapid Ebola test on the company's new Check4 platform.

"This is the new internet of things for diagnostics," said IdentifySensors CEO Greg Hummer. "Current molecular tests are old, slow, expensive and require skilled labor. Our rapid detection platform solves that through electronic circuits that connect instantly to cloud-based algorithms and healthcare software systems."

Related Links:
IdentifySensors Biologics